NO20045561L - 3'[(2Z)-(2-(3,4-dimetylfenyl)-1,5-dihydro-3-metyl-5-okso-41-I-pyrazol-4-yliden]hydrazin]-2'-hydroksy-(1,1'-bifenyl]-3-karboksy lsyre bis-(monoetanolamin) - Google Patents

3'[(2Z)-(2-(3,4-dimetylfenyl)-1,5-dihydro-3-metyl-5-okso-41-I-pyrazol-4-yliden]hydrazin]-2'-hydroksy-(1,1'-bifenyl]-3-karboksy lsyre bis-(monoetanolamin)

Info

Publication number
NO20045561L
NO20045561L NO20045561A NO20045561A NO20045561L NO 20045561 L NO20045561 L NO 20045561L NO 20045561 A NO20045561 A NO 20045561A NO 20045561 A NO20045561 A NO 20045561A NO 20045561 L NO20045561 L NO 20045561L
Authority
NO
Norway
Prior art keywords
ylidene
dimethylphenyl
monoethanolamine
biphenyl
dihydro
Prior art date
Application number
NO20045561A
Other languages
English (en)
Other versions
NO330160B1 (no
Inventor
Stephen Moore
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29584468&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20045561(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20045561L publication Critical patent/NO20045561L/no
Publication of NO330160B1 publication Critical patent/NO330160B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D231/08—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen or sulfur atoms directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En forbedret trombopoietinetterlikniner, bis-(monoetanolamin)-saltet til 3'-[2Z)-(l-3,4-dimetylfenyl)-1,5 -dihydro-3 -mety 1-5 -okso-4H-pyrazol-4-yliden]hydrazin] -2'hydroksy-( 1,1 '-bifenyl]-3 -karboksylsyre.
NO20045561A 2002-05-22 2004-12-20 Forbindelsen 3'[(2Z)-(2-(3,4-dimetylfenyl)-1,5-dihydro-3-metyl-5-okso-41-I-pyrazol-4-yliden]hydrazin]-2'-hydroksy-(1,1'-bifenyl]-3-karboksylsyre bis-(monoetanolamin), farmasoytisk sammensetning, fremgangsmate for fremstilling av sammensetningen samt forbindelsen, in vitro eller ex vivo fremgangsmate for a oke stimulering og eller overlevelse og anvendelse av en terapeutisk effektiv mengde av forbindelsen NO330160B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38287102P 2002-05-22 2002-05-22
PCT/US2003/016255 WO2003098992A2 (en) 2002-05-22 2003-05-21 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)

Publications (2)

Publication Number Publication Date
NO20045561L true NO20045561L (no) 2004-12-20
NO330160B1 NO330160B1 (no) 2011-02-28

Family

ID=29584468

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045561A NO330160B1 (no) 2002-05-22 2004-12-20 Forbindelsen 3'[(2Z)-(2-(3,4-dimetylfenyl)-1,5-dihydro-3-metyl-5-okso-41-I-pyrazol-4-yliden]hydrazin]-2'-hydroksy-(1,1'-bifenyl]-3-karboksylsyre bis-(monoetanolamin), farmasoytisk sammensetning, fremgangsmate for fremstilling av sammensetningen samt forbindelsen, in vitro eller ex vivo fremgangsmate for a oke stimulering og eller overlevelse og anvendelse av en terapeutisk effektiv mengde av forbindelsen

Country Status (29)

Country Link
US (6) US7547719B2 (no)
EP (2) EP1534390B1 (no)
JP (2) JP4612414B2 (no)
KR (2) KR20110113216A (no)
CN (1) CN100542530C (no)
AR (1) AR040083A1 (no)
AT (1) ATE452683T1 (no)
AU (1) AU2003241587B2 (no)
BR (1) BRPI0310094B8 (no)
CA (1) CA2486697C (no)
CY (1) CY1109912T1 (no)
DE (1) DE60330674D1 (no)
DK (1) DK1534390T3 (no)
ES (1) ES2338108T3 (no)
HK (1) HK1078039A1 (no)
IL (2) IL164966A0 (no)
IS (1) IS2770B (no)
LT (1) LTC1534390I2 (no)
MX (1) MXPA04011522A (no)
MY (1) MY142390A (no)
NO (1) NO330160B1 (no)
NZ (1) NZ536272A (no)
PL (1) PL212682B1 (no)
PT (1) PT1534390E (no)
RU (1) RU2284994C9 (no)
SI (1) SI1534390T1 (no)
TW (1) TWI280128B (no)
WO (1) WO2003098992A2 (no)
ZA (1) ZA200408701B (no)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
US20110212054A1 (en) * 2000-05-25 2011-09-01 Glaxosmithkline Llc. Thrombopoietin mimetics
TWI280128B (en) 2002-05-22 2007-05-01 Smithkline Beecham Corp 3'-[(2Z)-[1-(3,4- dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US20090298179A1 (en) * 2003-04-29 2009-12-03 Connie Erickson-Miller Methods For Treating Degenerative Diseases/Injuries
US20090048318A1 (en) * 2003-04-29 2009-02-19 Connie Erickson-Miller Methods for treating degenerative diseases/injuries
US20100004302A1 (en) * 2003-04-29 2010-01-07 Connie Erickson-Miller Methods for Treating Degenerative Diseases/Injuries
US20090143453A1 (en) * 2003-04-29 2009-06-04 Connie Erickson-Miller Methods for treating degenerative diseases/injuries
JP4895807B2 (ja) * 2003-04-29 2012-03-14 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 変性疾患／損傷の治療方法
SE0302486D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
TW200526638A (en) 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
WO2005118551A2 (en) * 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
WO2006047344A1 (en) 2004-10-25 2006-05-04 Ligand Pharmaceuticals, Inc. Thrombopoietin activity modulating compounds and methods
US20080286865A1 (en) * 2005-10-13 2008-11-20 Connie Lynn Erickson-Miller Methods for the Preservation of Platelet Efficacy During Storage
JP2009519352A (ja) * 2005-11-23 2009-05-14 リガンド・ファーマシューティカルズ・インコーポレイテッド トロンボポエチン活性調節化合物および方法
WO2007136566A2 (en) 2006-05-19 2007-11-29 Prorhythm, Inc. Ablation device with optimized input power profile and method of using the same
US20090304634A1 (en) * 2006-12-12 2009-12-10 Smithkline Beecham Corporation Novel Combinations
US20110160130A1 (en) * 2007-02-16 2011-06-30 Connie Erickson-Miller Cancer treatment method
UY30915A1 (es) 2007-02-16 2008-09-02 Smithkline Beecham Corp Método de tratamiento de canceres
US20110129550A1 (en) 2007-02-16 2011-06-02 Connie Erickson-Miller Cancer treatment method
ECSP077628A (es) * 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
AU2012201288B2 (en) * 2007-05-03 2014-05-01 Novartis Ag Novel pharmaceutical composition
US20090088371A1 (en) * 2007-08-28 2009-04-02 Rigel Pharmaceuticals, Inc. Combination therapy with syk kinase inhibitor
CN101888841B (zh) 2007-10-09 2012-09-26 宾夕法尼亚大学理事会 血小板生成素受体激动剂(TpoRA)杀死急性人骨髓样白血病细胞
CN101481352A (zh) * 2008-01-10 2009-07-15 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用
EP2414336A1 (en) * 2009-04-01 2012-02-08 Pliva Hrvatska D.O.O. Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof
US8476249B2 (en) 2009-05-07 2013-07-02 Glaxosmithkline Llc Method of treating thrombocytopenia
US8609693B2 (en) * 2009-05-29 2013-12-17 Glaxosmithkline Llc Methods of administration of thrombopoietin agonist compounds
CN101921232A (zh) 2009-06-11 2010-12-22 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物的盐,其制备方法及其在医药上的应用
EP2755955A4 (en) * 2011-09-13 2015-08-19 Glenmark Generics Ltd METHOD FOR PRODUCING SUBSTITUTED 3'-HYDRAZIN BIPHENYL-3-CARBOXYLIC ACID COMPOUNDS
GB201210857D0 (en) 2012-06-19 2012-08-01 Cambridge Entpr Ltd Transcription factor mediated programming towards megakaryocytes
US9763984B2 (en) 2012-12-21 2017-09-19 Astellas Institute For Regenerative Medicine Methods for production of platelets from pluripotent stem cells and compositions thereof
US9770437B2 (en) 2013-09-02 2017-09-26 Hetero Research Foundation Compositions of eltrombopag
WO2015111085A2 (en) 2014-01-27 2015-07-30 Cadila Healthcare Limited Processes for the preparation of eltrombopag and pharmaceutically acceptable salts, solvates and intermediates thereof
US10298884B2 (en) * 2014-05-09 2019-05-21 Honeywell International Inc. System and method of precision remote PTZ control of IP cameras
EP3188737A4 (en) 2014-09-05 2018-05-02 Hetero Research Foundation Crystalline form of eltrombopag free acid
WO2016055935A1 (en) 2014-10-06 2016-04-14 Glaxosmithkline Intellectual Property (No.2) Limited Combination of lysine-specific demethylase 1 inhibitor and thrombopoietin agonist
WO2017042839A1 (en) 2015-09-08 2017-03-16 Actavis Group Ptc Ehf. Novel eltrombopag salt and preparation thereof
WO2017081014A1 (en) * 2015-11-10 2017-05-18 Amneal Pharmaceuticals Company Gmbh Process for the preparation of eltrombopag olamine
CN106361719A (zh) * 2016-08-25 2017-02-01 浙江万晟药业有限公司 一种艾曲泊帕液体胶囊及其制备方法
CN106966984A (zh) * 2017-04-01 2017-07-21 常州制药厂有限公司 艾曲波帕二乙醇胺盐的制备方法
EP3395331B1 (en) 2017-04-26 2019-08-21 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising eltrombopag olamine
US11072586B2 (en) 2017-10-06 2021-07-27 Assia Chemical Industries Ltd. Solid state forms of eltrombopag choline
EP3409272B1 (en) 2018-03-07 2020-06-24 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical composition comprising eltrombopag olamine, reducing sugar, and polymeric binder
EP3604284B1 (en) 2018-08-02 2020-11-11 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Crystalline eltrombopag monoethanolamine salt form d
EP3604285B1 (en) 2018-08-02 2020-06-17 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Highly stable crystalline form d1 of the eltrombopag monoethanolamine salt
TR202014694A1 (tr) 2020-09-16 2022-03-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Eltrombopag olami̇n i̇çeren bi̇r kati oral farmasöri̇k formülasyon
WO2023111187A1 (en) 2021-12-15 2023-06-22 Galenicum Health, S.L.U Pharmaceutical compositions comprising eltrombopag

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE193350C (no)
US851444A (en) * 1905-11-13 1907-04-23 Agfa Ag Amido-oxy-sulfonic acid of phenylnaphthimidazol and process of making same.
GB779880A (en) 1953-02-27 1957-07-24 Ciba Ltd Functional derivatives of azo-dyestuffs containing sulphonic acid groups and processfor making them
US2809963A (en) * 1954-10-26 1957-10-15 Ciba Ltd Azo-dyestuffs
DE1046220B (de) 1956-04-21 1958-12-11 Bayer Ag Verfahren zur Herstellung von Monoazofarbstoffen und deren Metallkomplexverbindungen
GB826207A (en) 1956-07-23 1959-12-31 Bayer Ag ú´-ú´-dihydroxy-monoazo dyestuffs containing pyrrolidonyl residues and their metal complex compounds
US2950273A (en) * 1956-11-20 1960-08-23 Agfa Ag Process for the production of symmetrical and unsymmetrical azo compounds
US3366619A (en) * 1965-04-09 1968-01-30 Interchem Corp Disazo pyrazolone pigments
US4435417A (en) * 1981-02-20 1984-03-06 Gruppo Lepetit S.P.A. Antiinflammatory 3H-naphtho[1,2-d]imidazoles
JPS58103432A (ja) * 1981-12-14 1983-06-20 富士写真フイルム株式会社 固体撮像素子を用いた内視鏡装置
ES8503669A1 (es) * 1982-07-05 1985-03-01 Erba Farmitalia Procedimiento para preparar derivados n-imidazolilicos de compuestos biciclicos.
SU1162799A1 (ru) * 1982-07-09 1985-06-23 Витебский государственный медицинский институт Способ получени 4-арилгидразонов пиразолидинтриона-3,4,5
FR2559483B1 (fr) * 1984-02-10 1986-12-05 Sandoz Sa Composes heterocycliques contenant des groupes basiques et/ou cationiques, leur preparation et leur utilisation comme colorants
US4582831A (en) 1984-11-16 1986-04-15 Pfizer Inc. Anti-inflammatory polymorphic monoethanolamine salt of N-(2-pyridyl)-2-methyl-4-hydroxy-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide compound, composition, and method of use therefor
FI91869C (fi) * 1987-03-18 1994-08-25 Tanabe Seiyaku Co Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
US4880788A (en) * 1987-10-30 1989-11-14 Baylor College Of Medicine Method for preventing and treating thrombosis
US5326776A (en) * 1992-03-02 1994-07-05 Abbott Laboratories Angiotensin II receptor antagonists
IL109570A0 (en) 1993-05-17 1994-08-26 Fujisawa Pharmaceutical Co Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
EP0638617A1 (de) 1993-08-13 1995-02-15 Ciba-Geigy Ag Pigmentsalze
DE69423661T2 (de) * 1993-12-28 2000-11-23 Dainippon Printing Co Ltd Thermische Übertragungsaufzeichnungsschicht, die einen bestimmten Farbstoff verwendet
US5482546A (en) * 1994-03-30 1996-01-09 Canon Kabushiki Kaisha Dye, ink containing the same, and ink-jet recording method and instrument using the ink
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5746821A (en) * 1995-02-13 1998-05-05 Engelhard Corporation Pigment compositions
ES2303338T3 (es) 1995-06-07 2008-08-01 Glaxo Group Limited Peptidos y compuestos que se unen a un receptor de trombopoyetina.
US5622818A (en) * 1995-11-29 1997-04-22 Eastman Kodak Company Color photographic elements containing yellow colored magenta dye forming masking couplers
US5669967A (en) * 1996-05-30 1997-09-23 Engelhard Corporation Pigment compositions
PE91698A1 (es) * 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
US5932546A (en) * 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
SE9701398D0 (sv) 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
GB9715830D0 (en) * 1997-07-25 1997-10-01 Basf Ag Reactive dyes containing piperazine
WO1999011262A1 (en) 1997-09-02 1999-03-11 Roche Diagnostics Gmbh Mpl-receptor ligands, process for their preparation, medicaments containing them and their use for the treatment and prevention of thrombocytopaenia and anaemia
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US20010016568A1 (en) * 1997-10-31 2001-08-23 Juan I. Luengo Novel metal complexes
DE19851389A1 (de) * 1998-11-07 2000-05-11 Dystar Textilfarben Gmbh & Co Gelbe Farbstoffmischungen von wasserlöslichen faserreaktiven Azofarbstoffen und ihre Verwendung
GC0000177A (en) 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
US6265578B1 (en) * 1999-02-12 2001-07-24 Hoffmann-La Roche Inc. Pyrimidine-2,4,6-triones
CO5210907A1 (es) 1999-05-12 2002-10-30 Novartis Ag Solvatos de pometrozina, insecticidamente activos, composiciones que contienen estos compuestos y metodos tanto para producir dichos compuestos y composiciones como para controlar plagas animales con estas composiciones
CA2380206A1 (en) 1999-07-26 2001-02-01 Shionogi & Co., Ltd. Pharmaceutical compositions exhibiting thrombopoietin receptor agonism
ES2256038T3 (es) 1999-09-10 2006-07-16 Smithkline Beecham Corporation Mimeticos de trombopoyetina.
AU771460B2 (en) 1999-09-24 2004-03-25 Smithkline Beecham Corporation Thrombopoietin mimetics
EP1228051A1 (en) 1999-11-05 2002-08-07 SmithKline Beecham Corporation Semicarbazone derivatives and their use as thrombopoietin mimetics
ES2160560T1 (es) 1999-11-10 2001-11-16 Curacyte Ag Colorantes o,o'-dihidroxi-azoicos como constituyentes de medicamentos para el tratamiento de trombopenias.
GB9928805D0 (en) * 1999-12-07 2000-02-02 Karobio Ab Compounds active at the Glucocorticoid and Thyroid Hormone Receptors
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
US6214813B1 (en) * 2000-04-07 2001-04-10 Kinetek Pharmaceuticals, Inc. Pyrazole compounds
HUP0001417A2 (hu) 2000-04-07 2002-12-28 Sanofi-Synthelabo Gyógyászatilag alkalmazható új sók, eljárás előállításukra és azokat tartalmazó gyógyászati készítmények
US6436915B1 (en) 2000-04-07 2002-08-20 Kinetek Pharmaceuticals, Inc. Pyrazole compounds
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
JP2004513364A (ja) 2000-11-13 2004-04-30 コーニンクレッカ　フィリップス　エレクトロニクス　エヌ　ヴィ 表面欠陥の測定
EP1349613A4 (en) 2000-12-19 2005-09-21 Smithkline Beecham Corp THROMBOPOIETINMIMETIKA
JP2004532614A (ja) 2000-12-21 2004-10-28 スミスクライン・ビーチャム・コーポレイション 金属キレート化アゴニストによる細胞膜受容体の活性化の調節
US7169931B2 (en) * 2001-01-26 2007-01-30 Shionogi & Co., Ltd. Cyclic compounds exhibiting thrombopoietin receptor agonism
US20040063764A1 (en) * 2001-01-26 2004-04-01 Hiroshi Takemoto Halogen compounds having thrombopoietin receptor agonism
WO2002085343A1 (en) 2001-03-01 2002-10-31 Smithkline Beecham Corporation Thrombopoietin mimetics
JP3927001B2 (ja) 2001-06-15 2007-06-06 三菱化学株式会社 色素セット、インクセット並びに記録方法
MXPA04005204A (es) 2001-11-30 2005-11-04 Quadra Logic Tech Inc Derivados de hidrazonipirazol y su uso como terpapeuticos.
AU2003213673A1 (en) 2002-03-01 2003-09-16 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
TWI280128B (en) 2002-05-22 2007-05-01 Smithkline Beecham Corp 3'-[(2Z)-[1-(3,4- dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US7414040B2 (en) 2002-06-06 2008-08-19 Smithkline Beecham Corporation Thrombopoietin mimetics
WO2004054515A2 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Thrombopoietin mimetics
JP4895807B2 (ja) 2003-04-29 2012-03-14 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 変性疾患／損傷の治療方法
TW200526638A (en) 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline

Also Published As

Publication number Publication date
KR20040106569A (ko) 2004-12-17
LTC1534390I2 (lt) 2020-06-10
ES2338108T3 (es) 2010-05-04
KR101090643B1 (ko) 2011-12-07
US20110081312A1 (en) 2011-04-07
US8846024B2 (en) 2014-09-30
MY142390A (en) 2010-11-30
US20140037580A1 (en) 2014-02-06
CA2486697A1 (en) 2003-12-04
RU2284994C2 (ru) 2006-10-10
PL372440A1 (en) 2005-07-25
US20090291995A1 (en) 2009-11-26
WO2003098992A2 (en) 2003-12-04
EP2206533A2 (en) 2010-07-14
DE60330674D1 (de) 2010-02-04
BRPI0310094B8 (pt) 2021-05-25
BRPI0310094B1 (pt) 2018-10-23
US7795293B2 (en) 2010-09-14
TW200407128A (en) 2004-05-16
IL164966A0 (en) 2005-12-18
CY1109912T1 (el) 2014-09-10
US20150079030A1 (en) 2015-03-19
EP1534390A2 (en) 2005-06-01
LTPA2010007I1 (lt) 2019-11-11
PL212682B1 (pl) 2012-11-30
ZA200408701B (en) 2006-02-22
NO330160B1 (no) 2011-02-28
IS7573A (is) 2004-11-30
US20060178518A1 (en) 2006-08-10
EP1534390A4 (en) 2008-03-12
JP2010265317A (ja) 2010-11-25
RU2004137491A (ru) 2005-06-10
JP2005526143A (ja) 2005-09-02
AR040083A1 (es) 2005-03-16
RU2284994C9 (ru) 2021-02-24
TWI280128B (en) 2007-05-01
US8088813B2 (en) 2012-01-03
HK1078039A1 (en) 2006-03-03
KR20110113216A (ko) 2011-10-14
MXPA04011522A (es) 2005-02-14
IL199438A (en) 2011-06-30
BR0310094A (pt) 2005-02-15
US20120189576A1 (en) 2012-07-26
JP4612414B2 (ja) 2011-01-12
EP2206533A3 (en) 2010-09-15
SI1534390T1 (sl) 2010-05-31
WO2003098992A3 (en) 2004-03-25
NZ536272A (en) 2007-08-31
AU2003241587A1 (en) 2003-12-12
CN100542530C (zh) 2009-09-23
CA2486697C (en) 2009-01-06
EP1534390B1 (en) 2009-12-23
CN1652842A (zh) 2005-08-10
ATE452683T1 (de) 2010-01-15
AU2003241587B2 (en) 2007-10-04
IS2770B (is) 2011-12-15
US7547719B2 (en) 2009-06-16
PT1534390E (pt) 2010-03-08
DK1534390T3 (da) 2010-04-26

Similar Documents

Publication Publication Date Title
NO20045561L (no) 3'[(2Z)-(2-(3,4-dimetylfenyl)-1,5-dihydro-3-metyl-5-okso-41-I-pyrazol-4-yliden]hydrazin]-2'-hydroksy-(1,1'-bifenyl]-3-karboksy lsyre bis-(monoetanolamin)
HRP20080664A2 (en) Substituted pyridine herbicides
RS52323B (en) 2'-FLUORO-2'-DEOKSITETRAHIDROURIDINI KAO INHIBITORI CITIDIN DEAMINAZE
ES2193590T3 (es) Derivados de imidazol que tienen actividad inhibitoria frente a la farnesil transferasa y procedimiento para la preparacion de los mismos.
TR200002366T2 (tr) Herbisit aktif 3-hidroksi-4-aril-5-oksopirazolin türevleri.
RS52534B (en) MACROCYCLIC COMPOUNDS OF HINOXALINE AS HCV NS3 PROTEASE INHIBITORS
ATE372334T1 (de) Phenylpyrazolderivate als seh-inhibitoren
MA27609A1 (fr) Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
BRPI0516981A (pt) inibidores de mif
NO20061317L (no) Imidazopyridinderivater som induserbare NO-syntaseinhibatorer
UY3402Q (es) Diseno de tractor
ATE244699T1 (de) Substituierte anilinverbindungen
ATE292634T1 (de) Inhibitoren der alpha-l beta-2 vermittelten zelladhäsion
TW200502231A (en) Prodrugs of proton pump inhibitors
CY1107141T1 (el) Μεθοδος για την παρασκευη της 1-(2s,3s)-2-βενζυδρυλ-ν-(5-τριτ.-βουτυλ-2-μεθοξυβενζυλ)κινουκλιδιν-3-αμινης
EA200970124A1 (ru) Производные 2-арилиндола в качестве ингибиторов npges-1
NO20081207L (no) Isoquinolines as IGF-1R inhibitors
EP1650194A4 (en) INHIBITOR OF PROTEIN KINASE
AR036581A1 (es) Composicion herbicida
AP2002002466A0 (en) 3-heterocycliylpropanohydroxamic acid PCP INHIBITORS.
EA200300988A1 (ru) Производные фенил-гетероциклильных эфиров в качестве ингибиторов обратного захвата серотонина
MXPA06009711A (es) Uso de carboxipeptidasa g para combatir la toxicidad de antifolato.
EA201070194A1 (ru) Стабильная жидкая фармацевтическая композиция на основе тразодона
RS20060206A (en) Aminopyridine-derivatives as inducible no-synthase inhibitors
DE60228134D1 (de) Substituierte hydrazone als hemmer von cyclooxygenase-2

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: GLAXOSMITHKLINE LLC, US

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: GLAXOSMITHKLINE LLC, US

MK1K Patent expired